Spotlight welcomes Curasight
Today is the first day of trading in the research company Curasight, a Danish clinical phase II company based on more than a decade of research at Rigshospitalet and the University of Copenhagen.Curasight has developed the concept for PET imaging based on the receptor, Upar, a known biomarker for cancer aggressiveness. The concept is the basis for Curasight's technology, uTRACE®., which can identify cancer and tumor aggressiveness, tumor invasion and the formation of cancer metastases. Through this image, Curasight's technology facilitates diagnosis and the choice of cancer treatment.